Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of TP53 mutations on survival outcomes in the CAR-T era of large B-cell lymphoma.

Frontiers in immunology - 1 Jan 2026

Liu Rui, Fu Zhonghua, Yang Fan, Cao Miaomiao, Ma Lixia, Guo Yuelu, Deng Biping, Zheng Qinlong, Chen Chen, Jiang Bingxin, Chang Alex H, Li Danyang, Ke Xiaoyan, Hu Kai

Abstract excerpt

Purpose: TP53 mutations are among the strongest adverse prognostic factors in large B-cell lymphoma (LBCL) treated with chemoimmunotherapy. Whether this unfavorable prognostic impact persists in the era of chimeric antigen receptor (CAR) T-cell therapy remains controversial, largely due to the lack of non-CAR-T comparator cohorts. We aimed to explore whether the adverse prognostic impact of TP53 mutations differs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy, Adoptive

Share to Lymphoma, Large B-Cell, Diffuse

Share to Prognosis

Share to Receptors, Chimeric Antigen

Share to Treatment Outcome

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 42317374
DOI: 10.3389/fimmu.2026.1823432
PMCID: PMC13272385

Genes

TP53
CD19

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of TP53 mutations on survival outcomes in the CAR-T era of large B-cell lymphoma.PMID 42317374Read ↗

Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.Semantic proximity Read ↗

TP53 mutation and survival in aggressive B cell lymphoma.Semantic proximity Read ↗

Outcomes of Wild Type and TP53-Mutated B Cell Malignancy Patients Receiving CAR-T Cell Therapy: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial.Semantic proximity Read ↗

Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

Real-world routine diagnostic molecular analysis for TP53 mutational status is recommended over p53 immunohistochemistry in B-cell lymphomas.Semantic proximity Read ↗

TP53 mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era.Semantic proximity Read ↗

Prognostic Impact of TP53 Mutations in Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

Prognostic impact of TP53 mutations in diffuse large B-cell lymphoma.Semantic proximity Read ↗

TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma.Semantic proximity Read ↗

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.Semantic proximity Read ↗

Exploiting gene mutations and biomarkers to guide treatment recommendations in mantle cell lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.